7 completed, 6 unknown, 3 recruiting, 1 not yet recruiting. 8 Not applicable, 4 Phase 2, 3 Phase 1, 3 Phase 3, 2 Early Phase 1.
Follow Optic Nerve Injuries: new trials by email Literature Review of Optic Nerve Injuries trials Research Report on Optic Nerve Injuries
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy G01 Eye Drops 100μg/ml, G01 Eye Drops 200μg/ml, Placebo of G01 Eye Drops - Primary Open-Angle Glaucoma, Optic Nerve Injury | Phase 2 | Recruiting | Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. | 90 | 2026-03-18 | 2026-08-24 |
| Optic Nerve Stimulation To Prevent Visual Deficits After Endoscopic Cranial Approaches Optic Nerve Stimulation - Optic Nerve Injuries, Sellar Tumor | Not applicable | Not yet recruiting | University of California, San Francisco | 20 | 2024-08-01 | 2024-07-12 |
| Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial. Recombinant human erythropoietin 4,000 UI and 2,000 UI, Methylprednisolone succinate 500 mg - Toxic Optic Neuropathy, Treatment | Phase 2 / Phase 3 | Unknown | Asociación para Evitar la Ceguera en México | 18 | 2022-04-05 | 2023-02-28 |
| Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for NAION cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes - Eye Diseases, Retinitis Pigmentosa | Phase 1 | Recruiting | The Foundation for Orthopaedics and Regenerative Medicine | 20 | 2022-02-01 | 2026-10-16 |
| The Neuroprotective Effect of PEG-GCSF in the Traumatic Optic Neuropathy Neulasta® (pegfilgrastim) - Traumatic Optic Neuropathy | Early Phase 1 | Unknown | Buddhist Tzu Chi General Hospital | 20 | 2020-07-24 | 2023-12-13 |
| Diffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neuropathy. Neuroimaging, VEP - visual evoked potential, Ophthalmology examination. - Ischemic Optic Neuropathy, Optic Neuritis | Not applicable | Terminated | Medical University of Bialystok | 7 | 2020-01-01 | 2026-10-23 |
| The Phase I Study of Recombinant Human Nerve Growth Factor Injection Recombinant human nerve growth factor injection,experimental, Recombinant human nerve growth factor injection,single dose, Recombinant human nerve growth factor injection,multiple dose - Injury of Optic Nerve | Phase 1 | Unknown | Beijing Tongren Hospital | 86 | 2019-12-26 | 2021-08-17 |
| Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation Wharton jelly derived mesenchymal stem cell, Repetitive electromagnetic stimulation - Methanol Poisoning, Toxic Optic Neuropathy | Phase 3 | Completed | Ankara Universitesi Teknokent | 18 | 2019-04-01 | 2021-05-10 |
| Traumatic Optic Neuropathy Treatment Trial 2 Recombinant human erythropoietin - Traumatic Optic Neuropathy | Phase 3 | Completed | Iran University of Medical Sciences | 93 | 2018-01-06 | 2024-03-08 |
| Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy. Aflibercept, Mitomycin - Eye Diseases, Optic Nerve Damage | Early Phase 1 | Completed | Medical University of Lublin | 64 | 2017-06-14 | 2023-10-27 |
| Targeted Shortwave Diathermy Combined With Perceptual Training for Patients With Severe Traumatic Optic Neuropathy Rehabilitation: shortwave diathermy and perceptual training - Traumatic Optic Neuropathy | Not applicable | Unknown | Hunan Provincial People's Hospital | 60 | 2017-01-20 | 2021-12-01 |
| Stem Cell Ophthalmology Treatment Study II Arm 1 - Retinal Disease, Age-Related Macular Degeneration | Not applicable | Recruiting | MD Stem Cells | 500 | 2016-01-01 | 2026-06-29 |
| Traumatic Optic Neuropathy Treatment Trial (TONTT) Recombinant human erythropoietin (EPO), Observation, Methyl prednisolone - Traumatic Optic Neuropathy | Phase 1 / Phase 2 | Completed | Tehran University of Medical Sciences | 117 | 2015-02-01 | 2019-05-07 |
| Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION). RPh201, Placebo - Non-arteritic Ischemic Optic Neuropathy, Optic Nerve Injuries | Phase 2 | Completed | Regenera Pharma Ltd | 22 | 2014-02-01 | 2020-03-19 |
| Stem Cell Ophthalmology Treatment Study RB (Retrobulbar), ST (Subtenon), IV (Intravenous) - Retinal Disease, Macular Degeneration | Not applicable | Unknown | MD Stem Cells | 300 | 2012-08-01 | 2019-10-23 |
| Paraorbital-Occipital Alternating Current Stimulation Therapy for Optic Neuropathy (MCT_optnerve) tACS, Sham stimulation - Optic Nerve Diseases, Optic Nerve Injuries | Not applicable | Completed | University of Magdeburg | 90 | 2010-12-01 | 2017-01-30 |
| Surgery for Traumatic Optic Neuropathy Optic canal and optic nerve sheath decompression, methylprednisolone - Traumatic Optic Neuropathy | Not applicable | Unknown | Shanghai Changzheng Hospital | 2 | 2010-01-01 | 2016-03-17 |
| Trial of Alternating Current Stimulation in Optic Neuropathy Repetitive transorbital alternating current stimulation - Optic Nerve Diseases, Optic Nerve Injuries | Not applicable | Completed | University of Magdeburg | 22 | 2006-11-01 | 2020-11-09 |
Optic Nerve Diseases (5) · Eye Diseases (4) · Optic Neuropathy, Ischemic (4) · Glaucoma (3) · Macular Degeneration (3) · Optic Atrophy (3) · Retinitis Pigmentosa (3) · Toxic Optic Neuropathy (3) · Cone Dystrophy (2) · Cone-Rod Dystrophies (2) · Geographic Atrophy (2) · Neuromyelitis Optica (2) · Retinal Diseases (2) · Retinal Dystrophies (2)
Cranial Nerve Diseases (18) · Cranial Nerve Injuries (18) · Craniocerebral Trauma (18) · Nervous System Diseases (18) · Trauma, Nervous System (18) · Wounds and Injuries (18) · Eye Diseases (14) · Optic Nerve Diseases (13) · Cardiovascular Diseases (5) · Vascular Diseases (5) · Ocular Hypertension (4) · Pathological Conditions, Signs and Symptoms (4) · Chemically-Induced Disorders (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Drug-Related Side Effects and Adverse Reactions (3)
Control Groups (1) · Epoetin Alfa (1) · Immunoglobulins, Intravenous (1) · Jupiter (1) · Methylprednisolone (1) · Methylprednisolone Acetate (1) · Methylprednisolone Hemisuccinate (1) · Mitomycin (1) · Neuroimaging (1) · Observation (1) · Steroids (1) · Vitrectomy (1) · aflibercept (1) · pegfilgrastim (1)
MD Stem Cells (2) · University of Magdeburg (2) · Ankara Universitesi Teknokent (1) · Asociación para Evitar la Ceguera en México (1) · Beijing Tongren Hospital (1) · Buddhist Tzu Chi General Hospital (1) · Hunan Provincial People's Hospital (1) · Iran University of Medical Sciences (1) · Medical University of Bialystok (1) · Medical University of Lublin (1) · Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. (1) · Regenera Pharma Ltd (1) · Shanghai Changzheng Hospital (1) · Tehran University of Medical Sciences (1) · The Foundation for Orthopaedics and Regenerative Medicine (1)
China (4) · United States (4) · Germany (2) · Iran (2) · Poland (2) · Austria (1) · Greece (1) · Israel (1) · Mexico (1) · Taiwan (1) · Turkey (Türkiye) (1) · United Arab Emirates (1)
Jeffrey Weiss, MD (2) · Mohsen B Kashkouli, MD (2) · Steven Levy, MD (2) · Bernhard A Sabel, PhD (1) · Bernhard A Sabel, Prof. Dr. (1) · Ezequiel Goldschmidt, MD, PhD (1) · Lijun Hou, MD,PhD (1) · Octavio Turcio-Aceves, MD (1) · XiaoYe Wang (1) · Xiuli Zhao (1) · Yuanbo Liang (1)
PMID 26199618, PMID 26604914, PMID 27857759, PMID 27904503, PMID 22124039, PMID 27355577, PMID 29270420, PMID 30050918, PMID 31119146, PMID 31620478, PMID 32039263, PMID 32231088, PMID 32568958, PMID 33546345, PMID 34579767, PMID 39461733